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are higher after NMT while TRM is higher after HDT; and 4)
long term remissions suggest that NMT is associated with an
important graft vs lymphoma effect.
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STABLE LONG TERM ENGRAFTMENT AND AMELIORATION OF CLINICAL
PHENOTYPE FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FROM A MATCHED SIBLING DONOR FOR SICKLE CELL DISEASE
USING A REDUCED INTENSITY CONDITIONING REGIMEN
Krishnamurti, L.1; Wu, C.2; Baker, S.3; Yeager, A.M.4; Wagner, J.E.3
1. Children’s Hospital of Pittsburgh, Pittsburgh, PA; 2. Dana Farber
Cancer Institute, Boston, MD; 3. University of Minnesota, Minneapolis,
MN; 4. University of Pittsburgh Medical Center, Pittsburgh, PA.
Hematopoietic stem cell transplantation (HCT) from sibling
donors has been demonstrated to cure hemoglobinopathies such as
sickle cell disease (SCD) and Thalassemia. Concerns about high
regimen related toxicity (RRT) have prevented the use of HCT in
older patients, those with advanced organ damage or those without
a HLA matched related donor. Also, potential for late sequelae
such as chronic graft-versus-host disease (GVHD) and infertility
have limited the acceptance of this treatment even by eligible
patients. HCT following a reduced intensity conditioning (RIC)
regimen has the potential for reducing toxicity and potentially
making this curative therapy more acceptable and applicable to this
group of patients. We initiated a pilot study to evaluate the safety
and efﬁcacy of HCT following a RIC regimen for patients with
high risk hemoglobinopathies. We report stable long term engraft-
ment with amelioration of clinical phenotype in the ﬁrst three
patients with SCD receiving HCT (unmodiﬁed bone marrow)
from a matched sibling donor, on this study. The conditioning
regimen consisted of Busulfan 2 mg/kg orally q 12 hr 2 days (0.8
mg/kg IV q 6 hr  2 days for patient #3), Fludarabine 35 mg/m2/
dose IV daily  5 days, antithymocyte globulin 30 mg/kg/dose IV
daily  5 days and total lymphoid irradiation administered as a
single fraction of 500 cGy with shielding of the liver, lungs, heart,
and gonads. Prophylaxis for GVHD consisted of cyclosporine A
and Mycophenolate mofetil. Clinical characteristics of the patients
and outcomes are summarized in Table 1. The preparative regi-
men was well tolerated with no serious infections or mucositis in
any patient. Nadir of absolute neutrophil count was 140–200 
109/L. Nadir of platelet count was 25–40  109/L. Transfusion
requirements were modest (3 PRBC and 3–5 platelet transfusions).
All patients are off immunosuppressive medications. Recovery of
splenic function was observed except in patient #2 had who had
prior splenectomy. No patient has had any recurrence of previous
sickle cell related symptoms such as stroke, pain crisis, priapism or
acute chest syndrome. End-organ changes are stable in all patients.
Lineage-speciﬁc chimerism analysis (patient #3) suggest predomi-
nance of donor erythropoiesis. These ﬁndings indicate that HCT
for sickle cell disease following a RIC regimen is well tolerated and
can lead to stable long term engraftment with amelioration of
clinical phenotype and stabilization of end- organ damage.
Clinical Characteristics of Patients With Sickle Cell Disease
Undergoing HCT From a Matched Sibling Donor Following a
Reduced Intensity Conditioning Regimen
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INTRAVENOUS BUSULFAN DOSED FOUR TIMES DAILY OR ONCE DAILY
AS PART OF THE STANDARD BUCY PREPARATIVE REGIMEN FOR AL-
LOGENEIC STEM CELL TRANSPLANTATION
Shaughnessy, P.J.; Bachier, C.; Alexander, L.; Bowen, B.; LeMaistre,
C.F. Texas Transplant Institute, San Antonio, TX.
Intravenous busulfan (IVBu) (Busulfex ESP Pharma) is now
regularly substituted for oral busulfan as part of the standard
busulfan and cyclophosphamide (BuCy) preparative regimen for
allogeneic stem cell transplantation (ASCT). Oral busulfan was
originally dosed 4 times daily, which led to the current accepted
dosing schedule for IVBu. Pharmacokinetics (PK) and busulfan
clearance allow for once daily dosing now that IVBu is available.
We performed a retrospective review of 36 consecutive patients
who received the BuCy preparative regimen with IVBu prior to
ASCT. Twenty-one males and 15 females with a median age of 46
years (23–64) were treated for AML (n15), ALL (n1), CML
(n8), MDS (n8), NHL (n2), and multiple myeloma (n2).
IVBu was dosed 0.8 mg/kg 4 times daily for 16 doses (n16) or 3.2
mg/kg once daily for 4 doses (n20) on days 7 to 4, and
cyclophosphamide was dosed 60 mg/kg once daily for two doses on
days 3 and 2. IVBu was dosed by ideal or adjusted ideal body
weight and no PK studies were done. Bone marrow (n6) or
peripheral blood (n30) stem cells were infused on day 0 from
HLA matched siblings (n26) or unrelated donors (n9), and one
partially matched unrelated donor. Engraftment occurred in 34
patients (pts) (94%). Two pts who failed to engraft had bone
marrow grafts with low numbers of total mononuclear cells in-
fused. Regimen related toxicity (RRT) included mild VOD in 2 pts
(5%) that self resolved, with one pt receiving IVBu 4 times daily
and the other once daily. There was no seizure activity or non-
infectious interstitial pneumonitis attributed to RRT in any pa-
tient. Other RRT were not signiﬁcantly different between the
patients who received 4 times daily or once daily IVBu. Day 100
mortality was 17%, and at a median follow up of 12 months (1–54)
17 pts (47%) survive. Five of 16 pts (31%) survive who received 4
times daily IVBu, and 12 of 20 pts (60%) survive who received once
daily IVBu, however, most patients who received once daily IVBu
were treated more recently. Three patients received once daily
IVBu as outpatients. In conclusion, this small retrospective single
institution study revealed IVBu dosed once daily by ideal or ad-
justed ideal body weight appeared to have similar RRT, engraft-
ment, and survival compared to 4 times daily IVBu when used as
part of the BuCy preparative regimen for ASCT.
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HIGH RELAPSE RATE FOLLOWING ALEMTUZAMAB USE IN ALLOGENEIC
TRANSPLANTS FOR MYELOID HEMATOLOGIC MALIGNANCIES
Shea, T.C.1; Serody, J.1; Gabriel, D.1; Comeauu, T.1; Morris, D.2;
Irons, R.1; Harvey, D.3; Sharf, A.1; Krasnov, C.1; Dunphy, C.4; Ban-
derenko, N.4; Brecher, M.4 1. Department of Medicine, Bone Marrow
and Stem Cell Transplant Program; 2. Department of Radiation On-
cology; 3. Department of Pharmacy; 4. Department of Pathology and
Laboratory Medicine, UNC Hospitals, Lineberger Comprehensive Can-
cer Center and School of Medicine, Chapel Hill, NC.
Chakravarti (Blood, ‘02, p 1071) and others have described the
use of alemtuzamab in vivo for control of graft vs host disease in
allotransplantation. Control of GVHD has been good, but high
relapse rates and infectious complications have been reported. We
describe 47 pts, 16 women and 31 men, median age 49, and median
f/u 11 months who underwent matched related (31) or unrelated
(16) bone marrow (8), blood stem cell (38), or both (1), transplants
for hematologic malignancies. All AML pts had high-risk disease
deﬁned as beyond CR1 (11), CR1 with high risk cytogenetics (5),
AML with dysplasia (12), or failed prior autolograft (1). Three had
10% marrow blasts at time of transplant. All other pts had
multiply recurrent disease. All pts received Alemtuzamab at 20
mg/d  5 (17), 30 mg/d  3 (25) or lower doses (5) between days
8 through 4, followed by tacrolimus. Conditioning regimens
included 12.8 mg/kg IV busulfan, (27), 6.4 mg/kg IV busulfan (9),
melphalan 140 mg/m2 (6), or Cy/TBI (1). All non-TBI patients
received 30 mg/m2/d  5 of ﬂudarabine. Median recovery of ANC
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to 500/l and platelets 20,000/l w/o transfusion were 13 and
14 days, respectively. TRM included 1 pt each with intracranial
hemorrhage at d 8, multi-organ failure/sepsis at d 28, IPS/ARDS at
d 119, and grade IV GVHD with disseminated adenovirus. 2 of the
4 deaths were in MRD transplants; no serious cases of VOD were
observed. Grade 2–4 GVHD was seen in 5/16 evaluable MUD pts
and 3 of 29 (all sex mismatched) evaluable MRD pts. CMV reac-
tivation was seen in nearly all CMV sero pts; bk activation was
seen in 25 pts and hemorrhagic cystitis in 10. One case of PTLD,
3 graft failures, and adenovirus infection with nephritis, cystitis,
and transient cardiomyopathy in one patient, and fatal hepatitis in
a second patient were also seen. Relapse/# evaluable for different
diseases are: AML 12/26 (46%), imatinib-resistant CML 3/3 MDS
0/5, MM 3/3, NHL 0/3, ALL 0/3, CLL 0/2. Relapse rates in
evaluable MRD pts, 15/29 (52%), were statistically higher com-
pared to MUD pts, 3/16 (19%) (p  .055); marrow (2/8) vs BSC,
(16/37), were comparable. Alemtuzamab has been effective at con-
trolling GVHD but infectious complications are common and high
relapse rates preclude routine use of this approach in MRD pa-
tients with advanced myeloid diseases. Current use of this agent is
depending on donor (MRD vs MUD) and disease (myeloid vs
other) status.
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MISSING KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) LIGAND
CONFERS PROTECTION FROM RELAPSE IN RECIPIENTS OF UNRELATED
HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR AML
Hsu, K.C.1; Malkki, M.2; Gooley, T.A.2; Dupont, B.3; Petersdorf,
E.W.2, International Histocompatibility Working Group HCT-KIR
Component. 1. Memorial Sloan-Kettering Cancer Center, New York,
NY; 2. Fred Hutchinson Cancer Research Center, Seattle, WA; 3.
Sloan-Kettering Institute for Cancer Research, New York, NY.
The relationship between donor inhibitory KIR and recipient
HLA has been proposed as the basis for KIR-driven alloreactivity
by donor natural killer (NK) cells, leading to higher overall survival
(OS) and a reduction in relapse, graft-versus-host disease (GVHD)
and graft rejection in high-risk acute myelogenous leukemia
(AML) patients undergoing HLA-mismatched transplants. Previ-
ous analyses of KIR effects on HLA-mismatched HCT have ap-
plied a “KIR ligand incompatibility model,” which predicts NK
alloreactivity when donors with class I ligands for inhibitory KIR
are paired with recipients lacking the particular class I ligand
group. We have developed an algorithm that recognizes that pop-
ulation frequencies for inhibitory KIR2DL2/3, -2DL1, and -3DL1
are close to 100%, whereas the corresponding class I ligands (HLA
C1-group, C2-group, or Bw4) have population frequencies that
deviate greatly from 100%, leading to the frequent situation of
“missing KIR ligand,” even in HLA-matched transplants. The
“missing KIR ligand model” was applied in an analysis of 1765
unrelated donor HLA-A, -B, -C, -DRB1, and -DQB1 matched and
mismatched HCT pairs from the IHWG. All patients received
myeloablative conditioning followed by infusion of a T-replete
allograft. Using the “missing KIR ligand model,” KIR ligand ab-
sence/presence was correlated with overall survival (OS) and re-
lapse (Table). There was no beneﬁt in OS or relapse for ALL or
CML patients lacking KIR ligand. In contrast, AML patients
lacking KIR ligand demonstrated a signiﬁcantly lower relapse rate
(p0.001), that could be exclusively attributed to the lack of the
HLA C2-group ligand for donor KIR2DL1 (p
0.0001). The
lower relapse likely contributes to the higher OS (p0.04) seen in
these patients. Comparison of the “missing KIR ligand” and “KIR
ligand incompatibility” algorithms was then performed for AML/
MDS (n176), ALL (n137), and CML (n320) patients and
unrelated donors mismatched at HLA-B and/or HLA-C. Neither
model showed a beneﬁt in OS or relapse for any disease group with
exception of the missing ligand model in AML for relapse
(p0.008) This study indicates that lack of HLA C2-group ligand
in the patient with AML is associated with a lower risk of relapse
and improved overall survival, implying that release from
KIR2DL1 inhibition enhances donor NK alloreactivity against
AML. Adoptive immunotherapy with donor NK infusion may be
particularly beneﬁcial in these patients.
Missing KIR Ligand Algorithm and Disease-Speciﬁc Outcome
Overall Mortality Relapse
Hazard Ratio p-Value Hazard Ratio p-Value
AML/MDS
All ligands present (n  105) 1 — 1 —
Any KIR ligand absent (n 
373) 0.86 0.27 0.55 0.001
HLA C2-Group ligand absent
(n  149) 0.73 0.04 0.34 <0.0001
CML
All ligands present (n  230) 1 — 1 —
Any KIR ligand absent (n 
683) 1.1 0.39 1.08 0.68
ALL
All ligands present (n  77) 1 — 1 —
Any KIR ligand absent (n 
297) 1.12 0.49 1.17 0.56
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TRANSFUSIONAL IRON BURDEN AFTER BONE MARROW TRANSPLAN-
TATION
Jastaniah, W.A.1; Harmatz, P.2; Pakbaz, Z.2; Singer, T.2; Fischer, R.2;
Vichinsky, E.2; Walters, M.C.2 1. British Columbia’s Children’s Hos-
pital, Vancouver, BC, Canada; 2. Children’s Hospital Oakland, Oak-
land, CA.
Background: The signiﬁcance of transfusional iron overload
post-BMT for sickle cell disease (SCD) and hematological malig-
nancies has not been well deﬁned. Hence, we performed tests to
assess iron burden before and after BMT that included: serum iron,
ferritin, TIBC, and liver iron concentration (LIC) by liver biopsy
and/or SQUID biosusceptometer (Ferritometer, Model 5700,
Tristan Technologies, San Diego) under the standardized Ham-
burg-Torino-Oakland protocol. We compared results in children
with SCD and AML to those with thalassemia major (TM). Re-
sults: Fifteen children [SCD (N4), TM (N6), and AML
(N5)] received conventional myeloablative allografting at Chil-
dren’s Hospital Oakland (2000–2003). The mean (	SD) age (y) at
BMT was 10	 2.3, 6.8	 5.1, and 5.4	 2.9 among SCD, TM, and
AML patients, respectively. The mean duration of transfusion
exposures was 2.5, 5, and 2 years, respectively. Results of pre-BMT
iron burden are summarized in the Table. Pre-BMT liver histol-
ogy was assessed in 6 patients (SCD 1 and TM 5). Inﬂammation
was present in 4 TM patients and portal ﬁbrosis in 1 SCD and 3
TM patients. Hepatic venoocclusive disease (VOD) developed in
5/15 patients. TM patients were more likely to develop VOD (80
vs 20%) and pre-BMT, nonspeciﬁc inﬂammatory liver changes
were observed in 60% of TM patients (versus 10% of others).
Post-BMT, six patients were treated by regular phlebotomy. There
was poor correlation between serum ferritin and LIC. The serum
ferritin and WBC normalized by 40 months among phlebotomized
patients. However, normalization of LIC required a longer period
of time. The amount of iron removed by phlebotomy correlated
with the change in LIC as measured by SQUID. Conclusion:
Pre-BMT, we observed a signiﬁcant iron burden in children with
SCD, TM, and AML, which, if untreated, persisted post-BMT.
Liver inﬂammation and VOD was increased in TM patients, which
might reﬂect liver injury that is inﬂuenced by the duration of
exposure rather than simply by the magnitude of iron overload.
Phlebotomy is effective in unloading iron post-BMT in SCD and
TM patients. This pilot study showed that serum ferritin is an
unreliable indicator of iron overload post-BMT. The signiﬁcance
of transfusional iron overload in patients with hematological ma-
lignancies remains uncertain, but this study suggests that there is
potential for hepatic injury post-BMT. Ongoing studies are being
conducted to better deﬁne the natural history of iron overload in
post-BMT patients.
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